

David S Baldwin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8781005/publications.pdf>

Version: 2024-02-01

213
papers

8,837
citations

50244

46
h-index

51562

86
g-index

222
all docs

222
docs citations

222
times ranked

8884
citing authors

#	ARTICLE	IF	CITATIONS
1	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 248-312.	1.3	661
2	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2005, 19, 567-596.	2.0	537
3	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014, 28, 403-439.	2.0	511
4	Generalised anxiety disorder. <i>Lancet</i> , The, 2006, 368, 2156-2166.	6.3	265
5	Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2011, 342, d1199-d1199.	2.4	236
6	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 162-214.	1.3	226
7	Paroxetine in social phobia/social anxiety disorder. <i>British Journal of Psychiatry</i> , 1999, 175, 120-126.	1.7	216
8	Escitalopram Therapy for Major Depression and Anxiety Disorders. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1583-1592.	0.9	211
9	Benzodiazepines: Risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , 2013, 27, 967-971.	2.0	177
10	What Is the Threshold for Symptomatic Response and Remission for Major Depressive Disorder, Panic Disorder, Social Anxiety Disorder, and Generalized Anxiety Disorder?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1428-1434.	1.1	177
11	Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 57, 46-62.	2.9	175
12	British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>Journal of Psychopharmacology</i> , 2017, 31, 519-552.	2.0	166
13	The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. <i>Journal of Psychopharmacology</i> , 2016, 30, 242-252.	2.0	132
14	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 212-218.	2.0	132
15	A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). <i>European Neuropsychopharmacology</i> , 2012, 22, 482-491.	0.3	130
16	Evidence-based pharmacological treatment of generalized anxiety disorder. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 697-710.	1.0	125
17	Escitalopram and paroxetine in the treatment of generalised anxiety disorder. <i>British Journal of Psychiatry</i> , 2006, 189, 264-272.	1.7	124
18	The economic consequences of social phobia. <i>Journal of Affective Disorders</i> , 2002, 68, 221-233.	2.0	123

#	ARTICLE	IF	CITATIONS
19	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 321-365.	1.3	118
20	The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. <i>World Psychiatry</i> , 2018, 17, 3-11.	4.8	112
21	Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2019, 79, 24-38.	2.0	112
22	Which Factors Predict Placebo Response in Anxiety Disorders and Major Depression?. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1741-1746.	1.1	108
23	Evidence-based pharmacotherapy of Generalized Anxiety Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 293-302.	1.0	105
24	Estimating the Prevalence and Impact of Antidepressant-Induced Sexual Dysfunction in 2 European Countries. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 204-210.	1.1	102
25	Discontinuation symptoms in depression and anxiety disorders. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 73.	1.0	97
26	The SSRIs: Advantages, disadvantages and differences. <i>Journal of Psychopharmacology</i> , 1995, 9, 163-178.	2.0	93
27	A neuroimmunological perspective on anxiety disorders. <i>Human Psychopharmacology</i> , 2012, 27, 6-14.	0.7	90
28	Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. <i>European Neuropsychopharmacology</i> , 2008, 18, 422-430.	0.3	81
29	The generalized anxiety spectrum: prevalence, onset, course and outcome. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 37-45.	1.8	81
30	A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2006, 21, 159-169.	0.9	80
31	Sexual dysfunction associated with antidepressant drugs. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 457-470.	1.0	78
32	Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. <i>Human Psychopharmacology</i> , 2010, 25, 17-29.	0.7	70
33	A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. <i>Journal of Affective Disorders</i> , 2016, 206, 140-150.	2.0	67
34	Role of dopamine in schizophrenia and Parkinson's disease. <i>British Journal of Nursing</i> , 1998, 7, 832-841.	0.3	65
35	Pregabalin for the treatment of generalized anxiety disorder: an update. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 883.	1.0	65
36	Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. <i>Psychopharmacology</i> , 2004, 176, 466-470.	1.5	64

#	ARTICLE	IF	CITATIONS
37	A systematic review of the predictors of health service utilisation by adults with mental disorders in the UK. <i>BMJ Open</i> , 2015, 5, e007575.	0.8	62
38	Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. <i>Journal of Psychopharmacology</i> , 2006, 20, 91-96.	2.0	60
39	Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. <i>Current Medical Research and Opinion</i> , 2012, 28, 1717-1724.	0.9	60
40	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 22-28.	1.8	59
41	Antidepressant drugs and sexual dysfunction. <i>British Journal of Psychiatry</i> , 2013, 202, 396-397.	1.7	59
42	An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 510-516.	1.3	56
43	Research in anxiety disorders: From the bench to the bedside. <i>European Neuropsychopharmacology</i> , 2009, 19, 381-390.	0.3	53
44	Preferential Consolidation of Emotional Memory During Sleep: A Meta-Analysis. <i>Frontiers in Psychology</i> , 2019, 10, 1014.	1.1	52
45	How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. <i>Human Psychopharmacology</i> , 2009, 24, 269-275.	0.7	51
46	Inhalation of 7.5% Carbon Dioxide Increases Threat Processing in Humans. <i>Neuropsychopharmacology</i> , 2011, 36, 1557-1562.	2.8	51
47	Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. <i>Translational Psychiatry</i> , 2018, 8, 75.	2.4	51
48	Effects of antidepressant drugs on sexual function. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, 47-58.	1.2	47
49	Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. <i>Journal of Psychopharmacology</i> , 2015, 29, 1047-1060.	2.0	47
50	A critical review of the definition of "wellbeing"™ for doctors and their patients in a post Covid-19 era. <i>International Journal of Social Psychiatry</i> , 2021, 67, 984-991.	1.6	47
51	Investigation of Cortisol Levels in Patients with Anxiety Disorders: A Structured Review. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 18, 191-216.	0.8	46
52	Impact of Antidepressant Drugs on Sexual Function and Satisfaction. <i>CNS Drugs</i> , 2015, 29, 905-913.	2.7	44
53	Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder. <i>Brain, Behavior, and Immunity</i> , 2019, 81, 105-110.	2.0	44
54	Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. <i>Journal of Psychopharmacology</i> , 2012, 26, 778-783.	2.0	43

#	ARTICLE	IF	CITATIONS
55	Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence. <i>Drug Safety</i> , 2016, 39, 627-645.	1.4	43
56	Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2012, 27, 197-207.	0.9	42
57	Pharmacology for sleep disturbance in PTSD. <i>Human Psychopharmacology</i> , 2016, 31, 156-163.	0.7	41
58	Role of pregabalin in the treatment of generalized anxiety disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 185-191.	1.0	41
59	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 207-245.	1.8	40
60	Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function. <i>Psychopharmacology</i> , 2012, 223, 67-73.	1.5	40
61	Altered executive control network resting-state connectivity in social anxiety disorder. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 47-57.	1.3	39
62	Clinically relevant drug interactions in anxiety disorders. <i>Human Psychopharmacology</i> , 2012, 27, 239-253.	0.7	36
63	Effects of age and gender on elderly suicide rates in Catholic and Orthodox countries: an inadvertent neglect?. <i>International Journal of Geriatric Psychiatry</i> , 2000, 15, 904-910.	1.3	33
64	Escitalopram in the treatment of generalized anxiety disorder. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 443-449.	1.4	33
65	Lithium and sexual dysfunction: an under-researched area. <i>Human Psychopharmacology</i> , 2015, 30, 66-69.	0.7	33
66	Obsessive-compulsive symptoms and the Covid-19 pandemic: A rapid scoping review. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 132, 1086-1098.	2.9	32
67	Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets. <i>CNS Drugs</i> , 2017, 31, 307-317.	2.7	31
68	The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management. <i>World Psychiatry</i> , 2021, 20, 336-356.	4.8	31
69	The separation of adult separation anxiety disorder. <i>CNS Spectrums</i> , 2016, 21, 289-294.	0.7	30
70	Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. <i>Human Psychopharmacology</i> , 2008, 23, 527-532.	0.7	29
71	The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. <i>Journal of Anxiety Disorders</i> , 2014, 28, 741-746.	1.5	29
72	The future of antidepressant pharmacotherapy. <i>World Psychiatry</i> , 2003, 2, 3-8.	4.8	28

#	ARTICLE	IF	CITATIONS
73	Psychotropic Drugs and Sexual Dysfunction. <i>International Review of Psychiatry</i> , 1995, 7, 261-273.	1.4	27
74	Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , 1998, 12, 323-329.	2.0	27
75	Off-label prescribing by psychiatrists. <i>Psychiatric Bulletin</i> , 2000, 24, 415-417.	0.3	26
76	Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 12-15.	1.2	26
77	Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. <i>European Neuropsychopharmacology</i> , 2016, 26, 1062-1069.	0.3	26
78	Symptoms of fatigue and sleepiness in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 6, 9-15.	1.1	26
79	Pharmacological Treatment of Generalized Anxiety Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2009, 2, 453-467.	0.8	25
80	A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder. <i>Current Psychiatry Reports</i> , 2010, 12, 471-477.	2.1	25
81	The Effect of Prefrontal Transcranial Direct Current Stimulation on Attention Network Function in Healthy Volunteers. <i>Neuromodulation</i> , 2018, 21, 355-361.	0.4	25
82	Optimal treatment for obsessive compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2018, 33, 334-348.	0.9	25
83	Superiority of escitalopram to paroxetine in the treatment of depression. <i>European Neuropsychopharmacology</i> , 2009, 19, 229-237.	0.3	24
84	The Asian Cultural Identity Schedule: an investigation of culture and deliberate self-harm. <i>International Journal of Methods in Psychiatric Research</i> , 1999, 8, 212-218.	1.1	23
85	Treatment of Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 2007, 12, 28-35.	0.7	23
86	Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review. <i>Acta Neuropsychiatrica</i> , 2014, 26, 125-129.	1.0	23
87	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder?. <i>International Clinical Psychopharmacology</i> , 2016, 31, 347-352.	0.9	23
88	Identity in recovery from problematic alcohol use: A qualitative study of online mutual aid. <i>Drug and Alcohol Dependence</i> , 2017, 174, 17-22.	1.6	23
89	Room for Improvement in the Pharmacological Treatment of Anxiety Disorders. <i>Current Pharmaceutical Design</i> , 2008, 14, 3482-3491.	0.9	22
90	Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants. <i>Depression Research and Treatment</i> , 2013, 2013, 1-8.	0.7	22

#	ARTICLE	IF	CITATIONS
91	Oxytocin receptor and G-protein polymorphisms in patients with depression and separation anxiety. <i>Journal of Affective Disorders</i> , 2017, 218, 365-373.	2.0	22
92	Manifesto for a European Anxiety Disorders Research Network. <i>European Neuropsychopharmacology</i> , 2010, 20, 426-432.	0.3	21
93	Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. <i>European Neuropsychopharmacology</i> , 2012, 22, 137-142.	0.3	21
94	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 13-22.	1.8	21
95	Current and potential pharmacological and psychosocial interventions for anxiety symptoms and disorders in patients with schizophrenia: structured review. <i>Human Psychopharmacology</i> , 2017, 32, e2628.	0.7	21
96	Efficacy of vortioxetine on the physical symptoms of major depressive disorder. <i>Journal of Psychopharmacology</i> , 2018, 32, 1086-1097.	2.0	21
97	Structured review of the use of the Arizona sexual experiences scale in clinical settings. <i>Human Psychopharmacology</i> , 2020, 35, e2730.	0.7	21
98	Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. <i>Health Technology Assessment</i> , 2014, 18, 1-60.	1.3	20
99	Evaluating psychological interventions in a novel experimental human model of anxiety. <i>Journal of Psychiatric Research</i> , 2015, 63, 117-122.	1.5	20
100	Effects of repeated attachment security priming in outpatients with primary depressive disorders. <i>Journal of Affective Disorders</i> , 2018, 234, 201-206.	2.0	20
101	Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively. <i>CNS Drugs</i> , 2021, 35, 703-716.	2.7	19
102	Daytime intrusive thoughts and subjective insomnia symptoms. <i>Psychiatry Research</i> , 2015, 229, 1038-1042.	1.7	18
103	Covid-19: doctors must take control of their wellbeing. <i>BMJ, The</i> , 2020, 369, m1725.	3.0	18
104	Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom. <i>Annals of Pharmacotherapy</i> , 2006, 40, 1752-1758.	0.9	17
105	Antidepressants, withdrawal, and addiction; where are we now?. <i>Journal of Psychopharmacology</i> , 2019, 33, 655-659.	2.0	17
106	The influence of anxiety symptoms on clinical outcomes during baclofen treatment of alcohol use disorder: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 296-313.	2.9	17
107	A factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extended-release clinical trials. <i>Brain and Behavior</i> , 2013, 3, 738-746.	1.0	16
108	Health literacy and the pharmacological treatment of anxiety disorders: a systematic review. <i>Human Psychopharmacology</i> , 2014, 29, 211-215.	0.7	16

#	ARTICLE	IF	CITATIONS
109	Systematic review of blood transcriptome profiling in neuropsychiatric disorders: guidelines for biomarker discovery. <i>Human Psychopharmacology</i> , 2016, 31, 373-381.	0.7	16
110	Clinical experience with paroxetine in social anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2000, 15, S19-S24.	0.9	15
111	Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. <i>Journal of Psychopharmacology</i> , 2008, 22, 55-63.	2.0	15
112	Can we distinguish anxiety from depression?. <i>Psychopharmacology Bulletin</i> , 2002, 36 Suppl 2, 158-65.	0.0	15
113	Unmet needs in the pharmacological management of depression. <i>Human Psychopharmacology</i> , 2001, 16, S93-S99.	0.7	14
114	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. <i>Journal of Psychopharmacology</i> , 2001, 15, 161-165.	2.0	14
115	Escitalopram: efficacy and tolerability in the treatment of depression. <i>British Journal of Hospital Medicine</i> , 2002, 63, 668-671.	0.3	14
116	Manifesto for an international digital mental health network. <i>Digital Psychiatry</i> , 2019, 2, 14-24.	2.1	14
117	A neurobiological framework of separation anxiety and related phenotypes. <i>European Neuropsychopharmacology</i> , 2020, 33, 45-57.	0.3	14
118	Evidence-based Guidelines for Anxiety Disorders: Can They Improve Clinical Outcomes?. <i>CNS Spectrums</i> , 2006, 11, 34-39.	0.7	13
119	The Overlap of Obsessive-Compulsive Disorder and Social Phobia and its Treatment. <i>CNS Spectrums</i> , 2008, 13, 47-53.	0.7	13
120	Where is the room for improvement in the drug treatment of depression and anxiety?. <i>Human Psychopharmacology</i> , 2011, 26, 1-3.	0.7	13
121	Pharmacological Treatment of Panic Disorder. <i>Modern Problems of Pharmacopsychiatry</i> , 2013, 29, 128-143.	2.5	13
122	Prevalence, clinical correlates and IQ of suicidal ideation in drug naïve Chinese Han patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2019, 248, 59-64.	2.0	13
123	Effects of celecoxib augmentation of antidepressant or anxiolytic treatment on affective symptoms and inflammatory markers in patients with anxiety disorders: exploratory study. <i>International Clinical Psychopharmacology</i> , 2021, 36, 126-132.	0.9	13
124	Dysthymia. <i>CNS Drugs</i> , 1995, 4, 422-431.	2.7	12
125	Utility of the Health of the Nation Outcome Scales (HoNOS) in Predicting Mental Health Service Costs for Patients with Common Mental Health Problems: Historical Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0167103.	1.1	12
126	Developing a European research network to address unmet needs in anxiety disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2312-2317.	2.9	11

#	ARTICLE	IF	CITATIONS
127	Early effects of duloxetine on emotion recognition in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2015, 29, 634-641.	2.0	11
128	Genetic mechanisms of electroconvulsive therapy response in depression. <i>Human Psychopharmacology</i> , 2016, 31, 247-251.	0.7	11
129	Cancer, Benign Gynecology, and Sexual Function—Issues and Answers. <i>Journal of Sexual Medicine</i> , 2016, 13, 519-537.	0.3	11
130	Why we need more research into the placebo response in psychiatry. <i>Psychological Medicine</i> , 2020, 50, 2317-2323.	2.7	10
131	Esketamine and the Need for a New Type of Registry for Drugs With Abuse Potential. <i>American Journal of Psychiatry</i> , 2019, 176, 966-966.	4.0	9
132	Clinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications. <i>Addiction</i> , 2022, 117, 1472-1482.	1.7	9
133	Yogic breathing instruction in patients with treatment-resistant generalized anxiety disorder: Pilot study. <i>International Journal of Yoga</i> , 2019, 12, 78.	0.4	9
134	Functional Neuroimaging Correlates of Placebo Response in Patients With Depressive or Anxiety Disorders: A Systematic Review. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 433-447.	1.0	9
135	Anxiety symptom severity and functional recovery or relapse. <i>Annals of Clinical Psychiatry</i> , 2009, 21, 81-8.	0.6	9
136	Poor monitoring of physical health in patients referred to a mood disorders service. <i>Therapeutic Advances in Psychopharmacology</i> , 2015, 5, 22-25.	1.2	8
137	Sense and Sensibility When Prescribing “Off-Label”™ to Psychiatric Patients. <i>Current Pharmaceutical Design</i> , 2015, 21, 3276-3279.	0.9	8
138	On assessing potential efficacy for vortioxetine in generalized anxiety disorder. <i>European Neuropsychopharmacology</i> , 2012, 22, 841-843.	0.3	7
139	Should benzodiazepines still have a role in treating patients with anxiety disorders?. <i>Human Psychopharmacology</i> , 2012, 27, 237-238.	0.7	7
140	Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo-controlled trial of duloxetine. <i>Human Psychopharmacology</i> , 2016, 31, 332-340.	0.7	7
141	Attentional biases in patients with alcohol dependence: influence of coexisting psychopathology. <i>Human Psychopharmacology</i> , 2016, 31, 395-401.	0.7	7
142	Selective serotonin reuptake inhibitors in the treatment of generalized anxiety disorder. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 717-724.	1.4	6
143	Pharmacological treatment of social phobia. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 217-223.	0.2	6
144	The Pharmacologic Treatment of Patients With Generalized Anxiety Disorder: Where Are We Now and Where Are We Going?. <i>CNS Spectrums</i> , 2009, 14, 5-12.	0.7	6

#	ARTICLE	IF	CITATIONS
145	A joint European and South African research network in anxiety disorders. <i>Human Psychopharmacology</i> , 2012, 27, 4-5.	0.7	6
146	Vortioxetine in the treatment of major depressive disorder. <i>Future Neurology</i> , 2015, 10, 79-89.	0.9	6
147	Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?. <i>CNS Drugs</i> , 2020, 34, 163-169.	2.7	6
148	Ruminations and their correlates in depressive episodes: Between-group comparison in patients with unipolar or bipolar depression and healthy controls. <i>Journal of Affective Disorders</i> , 2021, 280, 1-6.	2.0	6
149	Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. <i>Journal of Affective Disorders</i> , 2022, 311, 588-594.	2.0	6
150	Cross-Sectional Associations of Depressive Symptom Severity and Functioning with Health Service Use by Older People in Low-and-Middle Income Countries. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 3774-3792.	1.2	5
151	Pharmacological provocation and prevention of suicidal behaviour. <i>International Review of Psychiatry</i> , 2000, 12, 54-61.	1.4	4
152	On predicting the response to antidepressant treatment. <i>Human Psychopharmacology</i> , 2012, 27, 343-344.	0.7	4
153	Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression. <i>International Clinical Psychopharmacology</i> , 2014, 29, 339-343.	0.9	4
154	Hair cortisol concentration in anxiety disorders: exploration of relationships with symptom severity and inflammatory markers. <i>Acta Neuropsychiatrica</i> , 2021, 33, 104-110.	1.0	4
155	Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. <i>Frontiers in Psychiatry</i> , 2021, 12, 784370.	1.3	4
156	Patient experience of lasting negative effects of psychological interventions for anxiety and depression in secondary mental health care services: a national cross-sectional study. <i>BMC Psychiatry</i> , 2021, 21, 578.	1.1	4
157	Feasibility and acceptability of transcranial stimulation in obsessive-compulsive symptoms (FEATSOCS): study protocol for a randomised controlled trial of transcranial direct current stimulation (tDCS) in obsessive-compulsive disorder (OCD). <i>Pilot and Feasibility Studies</i> , 2021, 7, 213.	0.5	4
158	Overcoming challenges in the management of schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , 1999, 3, 11-15.	1.2	3
159	The importance of long-term tolerability in achieving recovery. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 31-37.	1.2	3
160	Chapter 5.2 How effective are current drug treatments for anxiety disorders, and how could they be improved?. <i>Handbook of Behavioral Neuroscience</i> , 2008, , 395-411.	0.7	3
161	On reducing the duration of untreated illness in unipolar depression. <i>Human Psychopharmacology</i> , 2011, 26, 93-94.	0.7	3
162	Psychiatry should not become hostage to placebo: An alternative interpretation of antidepressant-placebo differences in the treatment response in depression. <i>European Neuropsychopharmacology</i> , 2012, 22, 782-786.	0.3	3

#	ARTICLE	IF	CITATIONS
163	Quality of case reports of adverse drug reactions with psychotropic drugs: a 25-year review. <i>Human Psychopharmacology</i> , 2013, 28, 413-420.	0.7	3
164	Benzodiazepines: Risks and Benefits. A Reconsideration. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 229-234.	0.4	3
165	Adult separation anxiety disorder: accepted but little understood. <i>Human Psychopharmacology</i> , 2015, 30, 1-3.	0.7	3
166	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry</i> , 2019, 6, 560-561.	3.7	3
167	Brain Functional Connectivity Correlates of Response in the 7.5% CO2 Inhalational Model of Generalized Anxiety Disorder: A Pilot Study. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 268-273.	1.0	3
168	Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110023.	1.2	3
169	Diverse predictors of treatment response to active medication and placebo in gambling disorder. <i>Journal of Psychiatric Research</i> , 2021, 144, 96-101.	1.5	3
170	Course and outcome of patients with alcohol use disorders following an alcohol intervention during hospital attendance: mixed method study. <i>BJPsych Open</i> , 2021, 7, e6.	0.3	3
171	Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence. <i>Journal of Psychopharmacology</i> , 2005, 19, 134-135.	2.0	2
172	Development and evaluation of psychotropic drugs. <i>Psychiatry (Abingdon, England)</i> , 2007, 6, 279-283.	0.2	2
173	Agomelatine improves symptoms of generalised anxiety disorder. <i>Evidence-Based Mental Health</i> , 2009, 12, 54-54.	2.2	2
174	Neurotic, stress-related and somatoform disorders. , 2010, , 453-491.		2
175	Overcoming barriers in the pharmacological treatment of anxiety disorders. <i>Neuropsychiatry</i> , 2013, 3, 33-44.	0.4	2
176	Does previous experience of antidepressants form the expectations necessary for a placebo response?. <i>British Journal of Psychiatry</i> , 2015, 207, 561-561.	1.7	2
177	A personal account of depressive illness and its antidepressant treatment. <i>International Clinical Psychopharmacology</i> , 2019, 34, 286-290.	0.9	2
178	The validity of the state-trait anxiety inventory and the brief scale for anxiety in an inpatient sample with alcohol use disorder. <i>Addiction</i> , 2021, 116, 3055-3068.	1.7	2
179	What is mental wellbeing?. <i>BJPsych Open</i> , 2021, 7, S236-S236.	0.3	2
180	Time to Reconsider Monoamine Oxidase Inhibitors for Obsessive Compulsive Disorder? A Case Series Using Phenyelzine. <i>Journal of Clinical Psychopharmacology</i> , 2021, Publish Ahead of Print, 461-464.	0.7	2

#	ARTICLE	IF	CITATIONS
181	Clinical evaluation of psychotropic drugs. <i>Psychiatry (Abingdon, England)</i> , 2004, 3, 14-17.	0.2	1
182	Editorial. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 235-235.	1.2	1
183	Agomelatine in the treatment of mood and anxiety disorders. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2010, 71, 153-156.	0.2	1
184	Evidence-based pharmacotherapy of generalized anxiety disorder. , 0, , 110-127.		1
185	Antidepressants for insomnia. <i>The Cochrane Library</i> , 2013, , .	1.5	1
186	Can cognitive behaviour therapy beneficially influence arousal mechanisms in psychosis?. <i>Human Psychopharmacology</i> , 2016, 31, 64-69.	0.7	1
187	A personal account of reducing and stopping antidepressant treatment. <i>International Clinical Psychopharmacology</i> , 2020, Publish Ahead of Print, 194-200.	0.9	1
188	The effect of attachment security priming and oxytocin on physiological responses to trauma films and subsequent intrusions. <i>Behaviour Research and Therapy</i> , 2021, 141, 103845.	1.6	1
189	Mental wellbeing in doctors: the measure matters! development of a core outcome set for measuring wellbeing in doctors. <i>BJPsych Open</i> , 2021, 7, S235-S236.	0.3	1
190	Safety and Tolerability of Antidepressants. , 2016, , 149-166.		1
191	Antipsychotic drugs for non-psychotic patients. <i>Psychiatric Bulletin</i> , 1999, 23, 416-418.	0.3	1
192	The first patient to receive olanzapine: A recollection. <i>Human Psychopharmacology</i> , 2021, 36, e2823.	0.7	1
193	Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. <i>CNS Spectrums</i> , 2023, 28, 46-52.	0.7	1
194	What medical students think about measurement of their well-being: cross-sectional survey and qualitative interviews. <i>BMJ Open</i> , 2022, 12, e056749.	0.8	1
195	Relationship of behavioral inhibition to separation anxiety in a sample (N=377) of adult individuals with mood and anxiety disorders. <i>Comprehensive Psychiatry</i> , 2022, 116, 152326.	1.5	1
196	Threat reversal learning and avoidance habits in generalised anxiety disorder. <i>Translational Psychiatry</i> , 2022, 12, .	2.4	1
197	TRENDS IN CARDIOLOGY: CURRENT VIEWS ON THE ETIOLOGY AND TREATMENT OF HYPERTENSION. <i>Journal of the American Geriatrics Society</i> , 1964, 12, 239-244.	1.3	0
198	More scrutiny required: An audit of the distribution of The Royal College of Psychiatrists' "Help is at Hand" leaflet on social phobia. <i>International Journal of Health Promotion and Education</i> , 1999, 37, 19-21.	0.4	0

#	ARTICLE	IF	CITATIONS
199	SSRIs in the Treatment of Generalized Anxiety Disorder. , 2001, , 193-209.		0
200	Discharging psychiatric patients from hospital. Psychiatric Bulletin, 2002, 26, 436-436.	0.3	0
201	Off-label prescribing. Psychiatric Bulletin, 2002, 26, 394-394.	0.3	0
202	Anxiety disorders: does one treatment fit all?. International Journal of Psychiatry in Clinical Practice, 2004, 8, 31-35.	1.2	0
203	Psychotropic Drug Directory 2003/04. The Professionals' Pocket Handbook & Aide Memoire. Stephen Bazire. Salisbury: Fivepin Publishing, 2003, £24.99 pb, 416 pp, ISBN: 0 95 448839 01. Psychiatric Bulletin, 2005, 29, 239-239.	0.3	0
204	Depression and Personality: Conceptual and Clinical Challenges. Edited by Michael Rosenbluth, Sidney H. Kennedy & R. Michael Bagby. American Psychiatric Publishing. 2005. 338 pp. US\$39.95 (pb). ISBN 1585621544. British Journal of Psychiatry, 2007, 190, 541-542.	1.7	0
205	Suicide by veterinary surgeons. Veterinary Record, 2008, 162, 355-356.	0.2	0
206	Treatment of generalised anxiety and somatoform disorders. , 0, , 525-541.		0
207	Introduction to Neuropsychopharmacology By Leslie L. Iversen, Susan D. Iversen, Floyd E. Bloom and Robert H. Roth Oxford University Press. 2009. £30.00 (pb). 558pp. ISBN: 9780195380538. British Journal of Psychiatry, 2010, 196, 499-500.	1.7	0
208	Authors'™ Reply to Alain Braillon's™ Comment on "Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence" Drug Safety, 2016, 39, 1153-1154.	1.4	0
209	Experimental Medicine Models in Generalized Anxiety Disorder and Social Anxiety Disorder. Handbook of Behavioral Neuroscience, 2019, 29, 363-374.	0.7	0
210	Drugs to Treat Anxiety and Insomnia. , 2020, , 268-289.		0
211	Quality of English inpatient mental health services for people with anxiety or depressive disorders: Findings and recommendations from the core audit of the National Clinical Audit of Anxiety and Depression. Comprehensive Psychiatry, 2021, 104, 152212.	1.5	0
212	Capacity for cortical excitation is reduced in psychotic disorders: An investigation of the TMS-EMG cortical silent period. Schizophrenia Research, 2022, 240, 73-77.	1.1	0
213	Authors'™ Reply to Ulrich: Comment on "Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively"™. CNS Drugs, 2022, 36, 103-103.	2.7	0